Home> Products> enhanced insulin secretion

{ "products": [ { "_id": "6842b74dc10e9000933fa1d7", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 50", "description": "TRELAQWK 50 is a modern, once-a-week oral antidiabetic medication containing Trelagliptin 50mg, developed to support adults with type 2 diabetes mellitus (T2DM). This formulation is designed to improve blood glucose regulation while offering patients the convenience of weekly dosing. Created under rigorous quality standards, TRELAQWK 50 combines therapeutic effectiveness with enhanced compliance and lifestyle ease.\n\nActive Ingredient:\nTrelagliptin 50mg\nA next-generation DPP-4 (Dipeptidyl Peptidase-4) inhibitor with an extended half-life, enabling once-weekly administration. It helps improve glycemic control by preserving incretin hormones that naturally support insulin secretion and reduce glucagon production.\n\nKey Advantages:\nDelivers long-lasting blood sugar control with just one tablet per week\n\nEnhances insulin production and decreases glucagon levels in a glucose-dependent manner\n\nEffectively lowers both fasting and post-meal blood sugar levels\n\nPerfect for patients who find daily medications challenging\n\nLowers the risk of hypoglycemia when not combined with insulin or sulfonylureas\n\nContributes to better HbA1c levels over continued use\n\nMechanism of Action:\nTRELAQWK 50 functions by inhibiting the DPP-4 enzyme, which degrades incretin hormones like GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide). By preventing their breakdown, Trelagliptin extends the action of these hormones, resulting in increased insulin release and reduced glucagon levels. This mechanism is particularly effective after meals, helping maintain optimal blood glucose levels throughout the week.\n\nUsage Instructions:\nTake one tablet weekly, ideally on the same day each week\n\nCan be taken with or without meals\n\nSwallow whole with water—do not crush or chew\n\nFollow your doctor's dosing guidelines exactly\n\nIf you miss a dose, do not take two tablets together; speak with your doctor for guidance\n\nPossible Side Effects:\nTRELAQWK 50 is usually well-tolerated. However, some individuals may notice:\n\nHeadache\n\nCommon cold-like symptoms (nasopharyngitis)\n\nMild diarrhea\n\nGastrointestinal discomfort\n\nRare allergic responses like skin rashes or itching\n\nShould any side effects persist or worsen, consult your healthcare provider immediately.", "price": 375.0, "discountamount": 112.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "offering patients", "worsen consult", "skin rashes", "chew follow", "meals swallow", "dpp4 enzyme", "sulfonylureas contributes", "enhanced compliance", "support adults", "trelaqwk 50trelaqwk 50", "hormones resulting", "hba1c levels", "tablet weekly ideally", "week usage instructions", "increased insulin release", "reduced glucagon levels", "degrades incretin hormones", "decreases glucagon levels", "preserving incretin hormones", "healthcare provider immediately", "side effects persist", "doctors dosing guidelines", "breakdown trelagliptin extends", "glp1 glucagonlike peptide1", "weekly dosing created" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2131, "imageuri": "https://productimages.withfloats.com/actual/6842b764900dc96c430f8095.png", "tileimageuri": "https://productimages.withfloats.com/tile/6842b764900dc96c430f8095.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-06-06T09:39:25.819Z", "updatedon": "2025-08-28T11:15:31.153Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-50/2131", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 50 mg", "category": "DIABETIC RANGE", "tags": [ "Trelagliptin in India", "Trelagliptin brand name", "trelagliptin 50 mg", "trelagliptin 50mg", "trelagliptin 50mg", "trelagliptin 50mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35c945c5e728a14d08ad8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin (25mg), Linagliptin (5mg)", "description": "GLIEMPAFLOZIN LINA 25mg/5mg is a combination medication designed for individuals managing type 2 diabetes mellitus. It contains Empagliflozin (25mg) and Linagliptin (5mg), two potent anti-diabetic agents that work together to control blood sugar levels effectively. This medication is typically prescribed to patients who require dual therapy to achieve optimal glycemic control when diet and exercise alone are insufficient.\n\n \nKey Benefits :\n \n\nEffective Blood Sugar Control: Regulates blood glucose levels efficiently in patients with type 2 diabetes.\n\nWeight Management: Empagliflozin promotes weight loss by removing excess glucose from the body.\n\nHeart and Kidney Benefits: Shown to provide cardiovascular and renal protection, reducing the risk of heart failure.\n\nLower Risk of Hypoglycemia: Minimal chances of low blood sugar episodes compared to other anti-diabetic medications.\n\nConvenient Dual Therapy: Combines two complementary mechanisms for enhanced glycemic control in a single tablet.\n\n \nHow Does It Work?\n \n\nEmpagliflozin (SGLT2 Inhibitor): This component blocks Sodium-Glucose Cotransporter-2 (SGLT2) in the kidneys, preventing glucose reabsorption and facilitating its elimination through urine. This leads to a significant reduction in blood sugar levels.\n\nLinagliptin (DPP-4 Inhibitor): It inhibits Dipeptidyl Peptidase-4 (DPP-4) enzyme, which increases incretin hormone levels. This enhances insulin secretion and suppresses glucagon production, leading to better post-meal glucose control.\n\n \nDirections for Use\n \n\nTake one tablet daily, preferably at the same time each day.\n\nSwallow the tablet whole with water, with or without food.\n\nFollow the dosage regimen prescribed by your healthcare provider.\n\nRegular monitoring of blood sugar levels is recommended.\n\n \nSide Effects\n \n\nAlthough GLIEMPAFLOZIN LINA 25mg/5mg is generally well-tolerated, some patients may experience:\n\nFrequent Urination: Due to glucose excretion through urine.\n\nDehydration or Thirst: Increased urination may lead to mild dehydration.\n\nUrinary Tract Infections (UTIs): A common side effect associated with SGLT2 inhibitors.\n\nNasal Congestion or Sore Throat: Occasionally observed with DPP-4 inhibitors.\n\nGastrointestinal Discomfort: Mild nausea or diarrhea in some cases.\n\nHypotension (Low Blood Pressure): Especially in patients with pre-existing conditions.\n\n ", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "urine dehydration", "preexisting conditions", "generally welltolerated", "food follow", "day swallow", "significant reduction", "single tablet", "complementary mechanisms", "provide cardiovascular", "body heart", "linagliptin 5mg", "empagliflozin 25mg", "glucose excretion", "typically prescribed", "tablet daily preferably", "combination medication designed", "dosage regimen prescribed", "removing excess glucose", "common side effect", "thirst increased urination", "gliempaflozin lina 25mg5mg", "recommended side effects", "blood sugar levels", "enhances insulin secretion", "enhanced glycemic control", "hypoglycemia minimal chances", "renal protection reducing", "kidney benefits shown", "require dual therapy", "potent antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2048, "imageuri": "https://productimages.withfloats.com/actual/67a35cb9b07d7c125c0f536d.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35cb9b07d7c125c0f536d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:41:56.39Z", "updatedon": "2025-03-17T11:04:56.55Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-25mg-linagliptin-5mg-/2048", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN LINA 25mg/ 5mg", "category": "DIABETIC RANGE", "tags": [ "empagliflozin-linagliptin 25-5 mg price", "Empagliflozin and Linagliptin brands in India", "empagliflozin-linagliptin 10-5 mg", "Fixed dose combination of Empagliflozin and Linagliptin Tablets Price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665eff188da3a81d5c69e749", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIDAPA 3D 10/100/1000 SR ", "description": "GLIDAPA 3D 10/100/1000 SR \nDapaflozin 10, Sitagliptin 100 mg & Metformin SR 1000 mg\nIntroduction\nGLIDAPA 3D 10/100/1000 SR is a comprehensive oral medication tailored for the treatment of Type 2 diabetes. This potent combination incorporates Dapagliflozin (10 mg), Sitagliptin (100 mg), and a higher dose of Metformin (1000 mg, sustained release), designed to effectively manage high blood sugar levels throughout the day.\n\nMechanism of Action\n\nDapagliflozin (10 mg): As an SGLT2 inhibitor, Dapagliflozin facilitates the removal of excess glucose from the body via the urine, helping to reduce blood glucose levels and also supporting weight loss and cardiovascular health.\nSitagliptin (100 mg): A DPP-4 inhibitor, Sitagliptin increases the levels of incretin hormones, which enhances the pancreatic response to high blood sugar after meals by increasing insulin production and decreasing glucagon secretion.\nMetformin SR (1000 mg): The higher dose of Metformin in this formulation works to decrease hepatic glucose production, improve insulin sensitivity, and reduce glucose absorption in the intestines. The sustained-release form minimizes gastrointestinal side effects and provides more stable blood sugar control.\nBenefits\nGLIDAPA 3D 10/100/1000 SR offers a potent therapeutic strategy by combining three drugs, each targeting a different aspect of diabetes management. This not only maximizes glucose control but also simplifies the treatment regimen, potentially enhancing patient compliance and reducing the risk of long-term complications.\n\nDosage and Administration\n\nDosage: The dosage should be tailored to the individual’s current health status, effectiveness of the treatment, and tolerability. Regular monitoring of blood glucose and adjustment of the dose may be necessary.\nAdministration: It is recommended to take the medication once daily in the morning, with or without food. The tablet should be swallowed whole to ensure proper release of Metformin over time.\nSide Effects\nCommon side effects may include urinary tract infections (due to Dapagliflozin), potential gastrointestinal disturbances such as nausea or diarrhea (common with Metformin), and a sore throat or nasopharyngitis associated with Sitagliptin. These side effects are generally mild and manageable.\n\nConclusion\nGLIDAPA 3D 10/100/1000 SR is a highly effective option for managing Type 2 diabetes, offering a strategic blend of three medications to control blood sugar levels, improve metabolic health, and reduce the risk of diabetes-related complications. This enhanced formulation is suitable for patients requiring a robust approach to diabetes management, emphasizing the importance of ongoing collaboration with healthcare providers to tailor and optimize treatment.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/glidapa-3d-10-100-1000-sr-134216\n\n\n\n\n\n", "price": 595.0, "discountamount": 178.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "time", "food", "body", "risk", "meals", "Order", "EMAIL", "urine", "nausea", "tablet", "Action", "morning", "1000 mg", "removal", "patients", "Benefits", "diarrhea", "Mechanism", "Conclusion", "Dapaflozin", "intestines", "adjustment", "importance", "individual", "weight loss", "Sitagliptin", "higher dose", "three drugs", "information", "sore throat", "tolerability", "Introduction", "sterisonline", "sterispharma", "Metformin SR", "Dapagliflozin", "CALL/WHATSAPP", "effectiveness", "proper release", "excess glucose", "SGLT2 inhibitor", "Type 2 diabetes", "robust approach", "DPP-4 inhibitor", "strategic blend", "nasopharyngitis", "glucose control", "metabolic health", "different aspect", "effective option", "sustained release", "treatment regimen", "incretin hormones", "three medications", "glucagon secretion", "Regular monitoring", "patient compliance", "glucose absorption", "insulin production", "potent combination", "pancreatic response", "diabetes management", "insulin sensitivity", "Common side effects", "enhanced formulation", "healthcare providers", "blood glucose levels", "ongoing collaboration", "cardiovascular health", "Administration Dosage", "current health status", "sustained-release form", "high blood sugar levels", "long-term complications", "urinary tract infections", "GLIDAPA 3D 10/100/1000 SR", "stable blood sugar control", "hepatic glucose production", "potent therapeutic strategy", "gastrointestinal side effects", "comprehensive oral medication", "diabetes-related complications", "potential gastrointestinal disturbances" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1303, "imageuri": "https://productimages.withfloats.com/actual/665eff1a8e77bb2c7151ebf4.png", "tileimageuri": "https://productimages.withfloats.com/tile/665eff1a8e77bb2c7151ebf4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:48:40.052Z", "updatedon": "2024-06-04T11:48:40.052Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glidapa-3d-10-100-1000-sr-/1303", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIDAPA 3D 10/100/1000 SR ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68e7a474f3481c1f16d3b038", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin (50mg), Metformin Hydrochloride (500mg) & Glimepiride (2mg)", "description": "Sitagliptin 50mg, Metformin Hydrochloride 500mg & Glimepiride 2mg is a combination oral medication designed for the effective management of type 2 diabetes mellitus. This triple-action formula works synergistically to control blood glucose levels by addressing insulin resistance, enhancing insulin secretion, and regulating post-meal sugar spikes. Ideal for patients who require more than one mechanism to maintain stable blood sugar, this combination is often prescribed when monotherapy or dual therapy is insufficient.\n\nUses\n\nManagement of Type 2 Diabetes Mellitus in adults.\n\nHelps in controlling fasting and postprandial blood glucose levels.\n\nRecommended for patients whose blood sugar is not adequately controlled with a single antidiabetic medicine.\n\nCan be used as part of a comprehensive diabetes management plan, including diet and exercise.\n\nKey Benefits\n\nDual Mechanism Control:\n\nMetformin Hydrochloride reduces hepatic glucose production and improves insulin sensitivity.\n\nGlimepiride stimulates pancreatic beta cells to secrete more insulin.\n\nSitagliptin enhances incretin hormones, leading to better regulation of post-meal glucose levels.\n\nEffective Blood Sugar Management:\nHelps maintain optimal fasting and postprandial glucose levels, reducing the risk of diabetes-related complications.\n\nConvenient Combination Therapy:\nCombines three mechanisms in a single tablet, reducing the pill burden and improving patient compliance.\n\nSupports Overall Health:\nHelps prevent long-term complications such as neuropathy, nephropathy, retinopathy, and cardiovascular risks associated with diabetes.\n\nPossible Side Effects\n\nWhile generally well-tolerated, some patients may experience:\n\nGastrointestinal issues: nausea, vomiting, diarrhea, or abdominal discomfort (mainly from Metformin).\n\nHypoglycemia (low blood sugar): more likely due to Glimepiride; symptoms include dizziness, sweating, or shakiness.\n\nAllergic reactions: rash, itching, or swelling in rare cases.\n\nOther mild effects: headache, fatigue, or minor changes in taste.\n\nNote: Patients should always consult their doctor before starting this combination and report any unusual symptoms immediately.\n\nConclusion\n\nThe Sitagliptin, Metformin Hydrochloride & Glimepiride combination provides a powerful, multi-targeted approach to managing type 2 diabetes. By tackling high blood sugar from different angles, it supports better glucose control, enhances overall quality of life, and reduces the risk of diabetes-related complications. When used alongside proper diet, exercise, and medical guidance, this combination can be a cornerstone in effective diabetes management.", "price": 180.0, "discountamount": 54.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2185, "imageuri": "https://productimages.withfloats.com/actual/68e7a47b040520d37b5e6b34.png", "tileimageuri": "https://productimages.withfloats.com/tile/68e7a47b040520d37b5e6b34.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-10-09T12:03:00.012Z", "updatedon": "2025-10-09T12:03:00.012Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-50mg-metformin-hydrochloride-500mg-glimepiride-2mg-/2185", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN GM", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-10-02T11:20:20.402Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b0256b813270ffac595cb0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 100", "description": "TRELAQWK 100 is an advanced oral antidiabetic medication containing Trelagliptin 100 mg, specifically designed for adults with type 2 diabetes mellitus (T2DM). Belonging to the class of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, this formulation helps improve blood glucose control when used along with a proper diet and regular exercise.\nWith its once-weekly dosage regimen, TRELAQWK 100 offers a convenient treatment option, enhancing patient compliance and simplifying long-term diabetes management.\nKey Ingredient\nTrelagliptin 100 mg\nA long-acting DPP-4 inhibitor that regulates blood glucose levels by enhancing incretin hormones. These incretins stimulate insulin secretion and suppress glucagon release, helping to achieve better glycemic control.\nKey Benefits of TRELAQWK 100\nWeekly dosing ensures greater convenience and adherence\nReduces both fasting and postprandial blood sugar levels\nSupports natural blood sugar regulation without weight gain\nLow risk of hypoglycemia, especially when used as monotherapy or with non-insulin therapies\nCan be prescribed as monotherapy or in combination with other antidiabetic agents like metformin or sulfonylureas\nHow TRELAQWK 100 Works\nTRELAQWK 100 functions by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).\nThese incretin hormones:\nStimulate insulin secretion in response to meals\nReduce glucagon release, lowering blood sugar levels\nThanks to its extended half-life, trelagliptin allows for once-weekly dosing, unlike other DPP-4 inhibitors that require daily administration.\nDirections for Use\nDosage: Take one tablet of TRELAQWK 100 once weekly, or as directed by your physician\nAdministration: May be taken with or without food, ideally on the same day each week\nMissed dose: Do not double the dose; consult your healthcare provider for guidance\nPossible Side Effects\nTRELAQWK 100 is usually well-tolerated, but some individuals may experience:\nMild headache\nNasopharyngitis (common cold-like symptoms)\nConstipation\nUpper respiratory tract infections\nRare skin allergies (rash, itching)\n👉 If you experience persistent abdominal pain, severe rashes, or symptoms suggestive of pancreatitis, stop the medication and seek medical care immediately.", "price": 550.0, "discountamount": 165.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2166, "imageuri": "https://productimages.withfloats.com/actual/68b0256ebb42c3d551ad314c.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b0256ebb42c3d551ad314c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:46:19.602Z", "updatedon": "2025-08-28T09:46:19.602Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-100/2166", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 100 mg", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b02393f5434d48fca8b8ca", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 50", "description": "TRELAQWK 50 is a modern oral antidiabetic tablet containing Trelagliptin 50 mg, specially developed for adults with type 2 diabetes mellitus. This once-weekly medication helps regulate blood sugar effectively, offering both convenience and strong clinical outcomes. With its advanced formulation, TRELAQWK 50 supports better glycemic control, making it easier for patients to lead a balanced and healthier lifestyle.\nManufactured under strict quality standards, TRELAQWK 50 ensures patient compliance, long-term safety, and efficacy in diabetes management.\nKey Ingredient\nTrelagliptin (50 mg):\nA unique, long-acting DPP-4 (dipeptidyl peptidase-4) inhibitor that allows weekly dosing, ensuring higher treatment adherence while maintaining effective control over blood glucose levels.\nKey Benefits of TRELAQWK 50\nProvides consistent blood sugar management with just one tablet per week\nEnhances insulin secretion while lowering glucagon levels in a glucose-dependent manner\nHelps reduce both fasting and postprandial blood glucose\nConvenient choice for patients with busy schedules who struggle with daily tablets\nLow risk of hypoglycemia when used as monotherapy\nSupports long-term improvement in HbA1c levels\nMechanism of Action – How TRELAQWK 50 Works\nTRELAQWK 50 works by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 and GIP. These incretins are vital for maintaining blood sugar balance. By prolonging incretin activity, trelagliptin:\nStimulates insulin secretion from the pancreas\nReduces glucagon release from alpha cells\nHelps lower blood sugar, particularly after meals\nThis mechanism provides both effective glycemic control and improved patient compliance.\nDirections for Use\nTake one tablet of TRELAQWK 50 once a week, on the same day each week\nCan be taken with or without food\nSwallow whole with a glass of water\nFollow your doctor’s advice for dosage adjustment\nDo not double the dose if missed; consult your healthcare provider\nPossible Side Effects\nTRELAQWK 50 is usually well-tolerated. However, some patients may experience:\nMild headache\nNasopharyngitis (cold-like symptoms)\nDiarrhea\nStomach discomfort or indigestion\nRare allergic reactions (rash, itching)\nIf any unusual or persistent side effects occur, seek medical advice promptly.", "price": 375.0, "discountamount": 112.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2165, "imageuri": "https://productimages.withfloats.com/actual/68b023971624ba892ffd8c69.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b023971624ba892ffd8c69.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:38:27.036Z", "updatedon": "2025-08-28T09:38:27.036Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-50/2165", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 50 mg", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6890aa548a215c65672372e1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH LINA 25/5", "description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2154, "imageuri": "https://productimages.withfloats.com/actual/6890aa58dd0bc098c3220f4c.png", "tileimageuri": "https://productimages.withfloats.com/tile/6890aa58dd0bc098c3220f4c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-04T12:40:52.619Z", "updatedon": "2025-08-04T12:40:52.619Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-lina-25-5/2154", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin and Linagliptin Tablets", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and Linagliptin Tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }